Scholar Rock (NASDAQ:SRRK) and Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Comparison

Scholar Rock (NASDAQ:SRRK) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Scholar Rock and Apogee Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1	0	12	5	3.17
Apogee Therapeutics	1	4	11	2	2.78

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 17.75%. Apogee Therapeutics has a consensus target price of $112.73, suggesting a potential upside of 43.77%. Given Apogee Therapeutics’ higher probable upside, analysts clearly believe Apogee Therapeutics is more favorable than Scholar Rock.

Earnings & Valuation

This table compares Scholar Rock and Apogee Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94 million	($3.59)	-13.25
Apogee Therapeutics	N/A	N/A	-$255.84 million	($4.33)	-18.11

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Scholar Rock has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Profitability

This table compares Scholar Rock and Apogee Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Insider and Institutional Ownership

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Scholar Rock beats Apogee Therapeutics on 7 of the 12 factors compared between the two stocks.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.